Home/Filings/4/0000899243-17-024245
4//SEC Filing

Cheung Wilson Wai-Shun 4

Accession 0000899243-17-024245

CIK 0000880771other

Filed

Oct 15, 8:00 PM ET

Accepted

Oct 16, 5:03 PM ET

Size

36.7 KB

Accession

0000899243-17-024245

Insider Transaction Report

Form 4
Period: 2017-10-13
Cheung Wilson Wai-Shun
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2017-10-13+75,000144,158 total
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-136,0000 total
    Common Stock (6,000 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2017-10-13$2.35/sh39,225$92,1790 total
    Exercise: $8.83Exp: 2025-03-16Common Stock (39,225 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2017-10-13$2.06/sh11,131$22,9300 total
    Exercise: $9.12Exp: 2026-03-15Common Stock (11,131 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$2.06/sh72,869$150,1100 total
    Exercise: $9.12Exp: 2026-03-15Common Stock (72,869 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-1312,0000 total
    Common Stock (12,000 underlying)
  • Exercise/Conversion

    Common Stock

    2017-10-13+52,00069,158 total
  • Disposition to Issuer

    Common Stock

    2017-10-13$11.18/sh144,158$1,611,6860 total
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$6.66/sh24,792$165,1150 total
    Exercise: $4.52Exp: 2024-03-14Common Stock (24,792 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$5.21/sh9,375$48,8440 total
    Exercise: $5.97Exp: 2023-08-09Common Stock (9,375 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-1325,0000 total
    Common Stock (25,000 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2017-10-13$1.53/sh10,651$16,2960 total
    Exercise: $9.65Exp: 2027-03-08Common Stock (10,651 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$1.53/sh73,349$112,2240 total
    Exercise: $9.65Exp: 2027-03-08Common Stock (73,349 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$2.35/sh44,775$105,2210 total
    Exercise: $8.83Exp: 2025-03-16Common Stock (44,775 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-139,0000 total
    Common Stock (9,000 underlying)
Footnotes (11)
  • [F1]Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
  • [F10]Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
  • [F11]Granted under Issuer's 2015 Equity Incentive Plan.
  • [F2]Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
  • [F3]Granted under Issuer's 2005 Equity Incentive Plan.
  • [F4]Under its terms the option became exercisable in installments with 25% vesting on August 9, 2014 and 2.0833% vesting each month thereafter until it became vested in full on August 9, 2017.
  • [F5]The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
  • [F6]Under its terms the option became exercisable in installments with 25% vesting on March 14, 2014 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2017.
  • [F7]Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
  • [F8]Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
  • [F9]Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.

Issuer

SCICLONE PHARMACEUTICALS INC

CIK 0000880771

Entity typeother

Related Parties

1
  • filerCIK 0001291656

Filing Metadata

Form type
4
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 5:03 PM ET
Size
36.7 KB